Patents Examined by Phillip Gambel
  • Hematopoietic progenitor cell populations having affinity for E-selectin / L-selectin
    Patent number: 10370642
    Abstract: The invention feature methods and compositions for treating hematopoietic disorders, inflammatory conditions, and cancer and providing stem cell therapy in a mammal.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: August 6, 2019
    Inventor: Robert Sackstein
  • Anti-VLA-4 antibodies
    Patent number: 10335485
    Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: July 2, 2019
    Assignee: Biogen MA Inc.
    Inventors: Alexey A. Lugovskoy, Frederick R. Taylor, Karen McLachlan
  • Nucleic acid construct encoding an agonistic anti-CD40 antibody and a type I interferon
    Patent number: 10329338
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: June 25, 2019
    Assignee: The Regents of the University of Colorado
    Inventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
  • Anti-C5a receptor antibodies
    Patent number: 10323097
    Abstract: The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: June 18, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Kristian Kjaergaard, Soeren Lund, Stefan Zahn, Louise H. Zeuthen, Anker J. Hansen
  • Nucleic acids encoding silent Fc variants of anti-CD40 antibodies
    Patent number: 10323096
    Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: June 18, 2019
    Assignee: Novartis AG
    Inventors: Christoph Heusser, James Rush, Karen Vincent
  • Subcutaneous administration of anti-CD74 antibody for systemic lupus erythematosus
    Patent number: 10322176
    Abstract: Disclosed are methods, compositions and uses of concentrated formulations of anti-CD74 antibody, of use for treating autoimmune diseases. In a specific non-limiting embodiment, the autoimmune disease is systemic lupus erythematosus (SLE). In a preferred embodiment, the anti-CD74 antibody is milatuzumab (IMMU-115). The antibody is administered subcutaneously, preferably at a dosage of 250 mg once a week for four weeks. The subcutaneous administration of anti-CD74 antibody ameliorates the symptoms of autoimmune diseases, with only manageable side effects.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: June 18, 2019
    Assignee: Immunomedics, Inc.
    Inventors: David M. Goldenberg, William A. Wegener
  • Humanized anti-complement factor C1Q antibodies
    Patent number: 10316081
    Abstract: The present disclosure is directed to humanized anti-C1q antibodies and methods of using them.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: June 11, 2019
    Assignee: Annexon, Inc.
    Inventors: Arnon Rosenthal, Michael Leviten
  • Anti-C5 antibodies and methods of treating complement-related diseases
    Patent number: 10280215
    Abstract: The present invention relates to an antibody against C5, and a method for preventing and treating complement-related diseases using the antibody, wherein the antibody against C5 is effectively usable in preventing and treating complement-related diseases by inhibiting complement activation.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: May 7, 2019
    Assignee: Seoul National University R&DB FOUNDATION
    Inventors: Junho Chung, Hyori Kim, Hwa Kyoung Lee, Won Jun Yang
  • Anti-OX40 antibodies
    Patent number: 10259882
    Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: April 16, 2019
    Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd
    Inventors: Marc Van Dijk, Ekaterina V. Breous-Nystrom, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Hao Tang, David A. Savitsky, Nicholas S. Wilson
  • Antibody therapeutics that bind CD137
    Patent number: 10259881
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CD137 antibodies. More specifically, there is disclosed fully human antibodies that bind CD137, CD137-antibody binding fragments and derivatives of such antibodies, and CD137-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression. Diseases amenable to treatment is selected from the group consisting of cancers, autoimmune diseases and viral infections.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: April 16, 2019
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: John Dixon Gray, Heyue Zhou
  • Anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
    Patent number: 10259879
    Abstract: Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: April 16, 2019
    Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventor: Randolph J. Noelle
  • CD31 peptides for the treatment of thrombotic or autoimmune disorders
    Patent number: 10253085
    Abstract: The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. The invention relates to peptides corresponding to fragments of CD31 that inhibit T-cell response, and to their use in the treatment of thrombotic disorders such as atherothrombosis and autoimmune disorders.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: April 9, 2019
    Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti
  • Methods of treating inflammatory and autoimmune diseases with natalizumab
    Patent number: 10233245
    Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: March 19, 2019
    Assignee: BIOGEN MA INC.
    Inventor: Ivan Lieberburg
  • Bispecific binding proteins that bind CD40 and mesothelin
    Patent number: 10233258
    Abstract: The present disclosure provides bispecific proteins that bind to two antigens, as well as their compositions, uses, and methods of making.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: March 19, 2019
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Yoshiko Akamatsu, Patricia Culp, Charles M. Forsyth, Ping Y. Huang, David Powers, Alan F. Wahl, Shiming Ye
  • Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodies
    Patent number: 10227400
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: March 12, 2019
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini, Yi Wang
  • Methods of treating aplastic anemia by administering anti-CD26 antibodies
    Patent number: 10208126
    Abstract: The present invention pertains to novel antibodies capable of binding to CD26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and/or preventing Graft-versus-Host Disease (GvHD), for use in treating Aplastic Anemia and/or for use in promoting engraftment after haematopoietic stem cell transplantation. Furthermore, the present invention provides pharmaceutical compositions comprising at least one antibody of the present invention, as well as provides a kit of parts.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: February 19, 2019
    Assignee: ADIENNE Pharma & Biotech SA
    Inventor: Antonio Francesco Di Naro
  • Polynucleotides encoding humanized anti-CD40 antibodies
    Patent number: 10201608
    Abstract: The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies generally block the ability of CD40 to bind CD154 and do so without activating the cell expressing CD40 (e.g., a B cell). The present antibodies or fragments thereof may be used to reduce complications associated with organ or tissue transplantation.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: February 12, 2019
    Assignee: Primatope Therapeutics Inc.
    Inventors: Bo Yu, Rijian Wang, Keith Reimann
  • Methods of treating immune diseases by administering antibody polypeptides that specifically bind CD40L
    Patent number: 10196451
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: February 5, 2019
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
  • Polynucleotides encoding anti-KIT antibodies
    Patent number: 10189907
    Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-mediated disorder or disease and methods of diagnosing a KIT-mediated disorder or disease using the antibodies described herein.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: January 29, 2019
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Yaron Hadari, Susanne Radke, Joseph Schlessinger, Yoshihisa Suzuki
  • Anti-Complement factor H antibodies
    Patent number: 10183988
    Abstract: Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.
    Type: Grant
    Filed: June 7, 2014
    Date of Patent: January 22, 2019
    Assignee: Duke University
    Inventors: Edward F. Patz, Jr., Michael J. Campa, Elizabeth Gottlin, Barton F. Haynes, Hua-Xin Liao, Anthony M. Moody